Alaleh Nouri Sells 6,892 Shares of PROCEPT BioRobotics (NASDAQ:PRCT) Stock

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) EVP Alaleh Nouri sold 6,892 shares of the business’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $23.70, for a total transaction of $163,340.40. Following the sale, the executive vice president owned 114,264 shares in the company, valued at $2,708,056.80. This trade represents a 5.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

PROCEPT BioRobotics Trading Down 4.3%

PROCEPT BioRobotics stock opened at $24.17 on Wednesday. The firm has a 50 day simple moving average of $28.96 and a 200-day simple moving average of $32.71. The company has a debt-to-equity ratio of 0.14, a current ratio of 6.85 and a quick ratio of 5.77. The stock has a market capitalization of $1.36 billion, a PE ratio of -14.13 and a beta of 1.02. PROCEPT BioRobotics Corporation has a 12-month low of $19.35 and a 12-month high of $66.85.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.21). The firm had revenue of $76.38 million for the quarter, compared to the consensus estimate of $93.70 million. PROCEPT BioRobotics had a negative return on equity of 25.13% and a negative net margin of 31.02%.PROCEPT BioRobotics’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.35) EPS. As a group, equities research analysts expect that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current fiscal year.

Analyst Ratings Changes

PRCT has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Thursday, January 22nd. TD Cowen dropped their price target on shares of PROCEPT BioRobotics from $50.00 to $34.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Bank of America downgraded shares of PROCEPT BioRobotics from a “neutral” rating to an “underperform” rating and cut their price target for the company from $38.00 to $20.00 in a report on Thursday, February 26th. Wall Street Zen lowered shares of PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, Morgan Stanley lowered their price objective on shares of PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 2nd. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $40.82.

PROCEPT BioRobotics News Summary

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Director Antal Rohit Desai completed large open‑market purchases (roughly $10M+ of stock across March 5–9), increasing his stake markedly — a strong insider vote of confidence that can support the share price. Read More.
• Positive Sentiment: Research coverage was started at Robert W. Baird (coverage can increase visibility and trading interest); that may help liquidity and analyst engagement. Read More.
• Neutral Sentiment: Two senior executives (EVPs Kevin Waters and Alaleh Nouri) sold modest stakes (~6.7k and ~6.9k shares on March 6); small insider sales can be personal liquidity and are smaller in scale than the director’s purchases. Read More.
• Negative Sentiment: Multiple law firms (Glancy Prongay Wolke & Rotter, Pomerantz, Frank R. Cruz, Levi & Korsinsky and others) have announced securities‑fraud investigations into PRCT, citing prior guidance/comments on revenue and handpiece pricing — this raises litigation risk, potential disclosures or restatements, and near‑term downward pressure on sentiment. Read More.
• Negative Sentiment: Recent quarterly results (Feb. 25) missed consensus: EPS and revenue came in below expectations — a key fundamental headwind that likely prompted analyst target downgrades and is feeding the ongoing scrutiny. Read More.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PRCT. Advisory Services Network LLC lifted its position in shares of PROCEPT BioRobotics by 1.3% in the 2nd quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock valued at $1,158,000 after acquiring an additional 250 shares in the last quarter. Vega Investment Solutions grew its position in PROCEPT BioRobotics by 52.0% during the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company’s stock worth $45,000 after purchasing an additional 265 shares in the last quarter. Frank Rimerman Advisors LLC raised its stake in PROCEPT BioRobotics by 0.3% during the 3rd quarter. Frank Rimerman Advisors LLC now owns 122,389 shares of the company’s stock valued at $4,368,000 after purchasing an additional 307 shares during the period. RiverPark Advisors LLC lifted its holdings in shares of PROCEPT BioRobotics by 22.5% in the second quarter. RiverPark Advisors LLC now owns 1,761 shares of the company’s stock valued at $101,000 after purchasing an additional 324 shares in the last quarter. Finally, Osaic Holdings Inc. lifted its holdings in shares of PROCEPT BioRobotics by 20.3% in the second quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock valued at $115,000 after purchasing an additional 337 shares in the last quarter. 89.46% of the stock is owned by hedge funds and other institutional investors.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.